Ampio Pharmaceuticals (AMPE)
(Delayed Data from OTC)
$0.00 USD
0.00 (0.00%)
Updated Sep 12, 2024 12:37 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Ampio Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 4 | 13 | 34 | 17 | 7 |
Receivables | 1 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 2 | 1 | 2 |
Total Current Assets | 6 | 13 | 36 | 18 | 8 |
Net Property & Equipment | 0 | 0 | 3 | 4 | 5 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 6 | 14 | 39 | 23 | 14 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 1 | 5 | 2 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 2 | 1 | 5 | 2 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 6 | 3 | 2 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2 | 2 | 12 | 5 | 8 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 246 | 246 | 245 | 218 | 191 |
Retained Earnings | -243 | -234 | -218 | -201 | -185 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 3 | 12 | 27 | 18 | 6 |
Total Liabilities & Shareholder's Equity | 6 | 14 | 39 | 23 | 14 |
Total Common Equity | 3 | 12 | 27 | 18 | 6 |
Shares Outstanding | 0.80 | 0.70 | 0.60 | 0.60 | 0.50 |
Book Value Per Share | 4.20 | 16.84 | 45.47 | 29.18 | 12.88 |
Fiscal Year End for Ampio Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | 4 | 6 | 7 |
Receivables | NA | NA | 1 | 1 | 1 |
Notes Receivable | NA | NA | 0 | 0 | 0 |
Inventories | NA | NA | 0 | 0 | 0 |
Other Current Assets | NA | NA | 1 | 1 | 1 |
Total Current Assets | NA | NA | 6 | 8 | 9 |
Net Property & Equipment | NA | NA | 0 | 0 | 0 |
Investments & Advances | NA | NA | 0 | 0 | 0 |
Other Non-Current Assets | NA | NA | 0 | 0 | 0 |
Deferred Charges | NA | NA | 0 | 0 | 0 |
Intangibles | NA | NA | 0 | 0 | 0 |
Deposits & Other Assets | NA | NA | 0 | 0 | 0 |
Total Assets | NA | NA | 6 | 8 | 9 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | 0 | 0 | 0 |
Accounts Payable | NA | NA | 2 | 2 | 2 |
Current Portion Long-Term Debt | NA | NA | 0 | 0 | 0 |
Current Portion Capital Leases | NA | NA | 0 | 0 | 0 |
Accrued Expenses | NA | NA | 0 | 0 | 0 |
Income Taxes Payable | NA | NA | 0 | 0 | 0 |
Other Current Liabilities | NA | NA | 0 | 0 | 0 |
Total Current Liabilities | NA | NA | 2 | 2 | 3 |
Mortgages | NA | NA | 0 | 0 | 0 |
Deferred Taxes/Income | NA | NA | 0 | 0 | 0 |
Convertible Debt | NA | NA | 0 | 0 | 0 |
Long-Term Debt | NA | NA | 0 | 0 | 0 |
Non-Current Capital Leases | NA | NA | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | NA | 0 | 0 | 0 |
Total Liabilities | NA | NA | 2 | 2 | 3 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | 0 | 0 | 0 |
Common Stock (Par) | NA | NA | 0 | 0 | 0 |
Capital Surplus | NA | NA | 246 | 246 | 246 |
Retained Earnings | NA | NA | -243 | -240 | -239 |
Other Equity | NA | NA | 0 | 0 | 0 |
Treasury Stock | NA | NA | 0 | 0 | 0 |
Total Shareholder's Equity | NA | NA | 3 | 5 | 7 |
Total Liabilities & Shareholder's Equity | NA | NA | 6 | 8 | 9 |
Total Common Equity | 0 | 0 | 3 | 5 | 7 |
Shares Outstanding | 1.10 | 1.10 | 0.80 | 0.70 | 0.70 |
Book Value Per Share | 0.00 | 0.00 | 4.20 | 7.69 | 9.37 |